DK200300114U3 - Faste tilstandsformer af ondansetron - Google Patents

Faste tilstandsformer af ondansetron Download PDF

Info

Publication number: DK200300114U3
Authority: DK; Denmark
Prior art keywords: ondansetron; base; solid; water; solution
Prior art date: 2003-01-09

Application number

DK200300114U

Other languages

Danish (da)

English (en)

Inventor

Westheim Raymond Joze Hubertus

Dalen Frans Van

Original Assignee

Synthon Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-09

Filing date

2003-04-08

Publication date

2004-04-23

2003-04-08 Application filed by Synthon Bv filed Critical Synthon Bv

2004-04-23 Application granted granted Critical

2004-04-23 Publication of DK200300114U3 publication Critical patent/DK200300114U3/da

Links

FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 title description 181
229960005343 ondansetron Drugs 0.000 title description 179
239000007787 solid Substances 0.000 title description 44
239000002585 base Substances 0.000 description 107
239000000203 mixture Substances 0.000 description 61
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
238000000034 method Methods 0.000 description 41
239000000243 solution Substances 0.000 description 41
239000002904 solvent Substances 0.000 description 41
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
238000002844 melting Methods 0.000 description 34
230000008018 melting Effects 0.000 description 34
239000003826 tablet Substances 0.000 description 34
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 23
239000000047 product Substances 0.000 description 20
239000002245 particle Substances 0.000 description 16
150000003839 salts Chemical class 0.000 description 16
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
238000006386 neutralization reaction Methods 0.000 description 15
239000002253 acid Substances 0.000 description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
239000000546 pharmaceutical excipient Substances 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
238000001938 differential scanning calorimetry curve Methods 0.000 description 11
239000011777 magnesium Substances 0.000 description 11
239000000463 material Substances 0.000 description 11
238000001556 precipitation Methods 0.000 description 11
238000010992 reflux Methods 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000007788 liquid Substances 0.000 description 10
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
239000008101 lactose Substances 0.000 description 9
229920000168 Microcrystalline cellulose Polymers 0.000 description 8
239000013078 crystal Substances 0.000 description 8
239000008108 microcrystalline cellulose Substances 0.000 description 8
235000019813 microcrystalline cellulose Nutrition 0.000 description 8
229940016286 microcrystalline cellulose Drugs 0.000 description 8
239000002244 precipitate Substances 0.000 description 8
229910052783 alkali metal Inorganic materials 0.000 description 7
150000001340 alkali metals Chemical class 0.000 description 7
238000001816 cooling Methods 0.000 description 7
239000012535 impurity Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
239000008188 pellet Substances 0.000 description 7
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
238000002425 crystallisation Methods 0.000 description 6
230000008025 crystallization Effects 0.000 description 6
238000000113 differential scanning calorimetry Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
238000002156 mixing Methods 0.000 description 6
229960004106 citric acid Drugs 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
239000012458 free base Substances 0.000 description 5
239000011521 glass Substances 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
230000003472 neutralizing effect Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000011282 treatment Methods 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
238000001914 filtration Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000003825 pressing Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 3
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
238000002441 X-ray diffraction Methods 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229960000770 ondansetron hydrochloride Drugs 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000002002 slurry Substances 0.000 description 3
229910001415 sodium ion Inorganic materials 0.000 description 3
239000008109 sodium starch glycolate Substances 0.000 description 3
229940079832 sodium starch glycolate Drugs 0.000 description 3
229920003109 sodium starch glycolate Polymers 0.000 description 3
238000002411 thermogravimetry Methods 0.000 description 3
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
-1 breastfeeding Chemical compound 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000007908 dry granulation Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
244000144992 flock Species 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
210000000582 semen Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000012439 solid excipient Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000005979 thermal decomposition reaction Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
GFQLILQFQHMEPF-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-9-methyl-2,3-dihydro-1h-carbazol-4-one;hydrochloride Chemical compound Cl.C12=CC=CC=C2N(C)C2=C1C(=O)C(CN(C)C)CC2 GFQLILQFQHMEPF-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102100023591 Polyphosphoinositide phosphatase Human genes 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229960002303 citric acid monohydrate Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
150000004292 cyclic ethers Chemical class 0.000 description 1
238000013461 design Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940047135 glycate Drugs 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
238000000227 grinding Methods 0.000 description 1
210000002837 heart atrium Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
VIOAGOMGEZTUHG-UHFFFAOYSA-L magnesium;2-hydroxyacetate;octadecanoate Chemical compound [Mg+2].OCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O VIOAGOMGEZTUHG-UHFFFAOYSA-L 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
229940043265 methyl isobutyl ketone Drugs 0.000 description 1
239000008185 minitablet Substances 0.000 description 1
150000004682 monohydrates Chemical group 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
101150008094 per1 gene Proteins 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
229960000999 sodium citrate dihydrate Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
229940072018 zofran Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK200300114U 2003-01-09 2003-04-08 Faste tilstandsformer af ondansetron DK200300114U3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US43878003P	2003-01-09	2003-01-09

Publications (1)

Publication Number	Publication Date
DK200300114U3 true DK200300114U3 (da)	2004-04-23

Family

ID=23741979

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK200300114U DK200300114U3 (da)	2003-01-09	2003-04-08	Faste tilstandsformer af ondansetron

Country Status (9)

Country	Link
US (1)	US20040198794A1 (fr)
EP (1)	EP1581519A1 (fr)
AU (2)	AU2003222765A1 (fr)
DK (1)	DK200300114U3 (fr)
FI (1)	FI6164U1 (fr)
FR (1)	FR2849852A1 (fr)
GB (1)	GB2398566A (fr)
NL (1)	NL1022893C2 (fr)
WO (1)	WO2004063189A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2238001B1 (es)	2004-01-21	2006-11-01	Vita Cientifica, S.L.	Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
CA2565854A1 (fr)	2004-05-07	2005-11-17	Taro Pharmaceutical Industries Ltd.	Procede de preparation de chlorhydrate dihydrate d'ondansetron ayant une granulometrie definie
EP1828141A4 (fr) *	2004-10-26	2009-04-01	Ipca Lab Ltd	Procede monotope de preparation de l'agent antiemetique 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazol-4-one

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4695578A (en) *	1984-01-25	1987-09-22	Glaxo Group Limited	1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
IL74165A (en) *	1984-01-25	1988-11-15	Glaxo Group Ltd	1,2,3,9-tetrahydro-3-(1h-imidazole-1-yl methyl)-4h-carbazol-4-one compounds,their preparation and pharmaceutical compositions containing them
EP0191562B1 (fr) *	1985-01-23	1991-07-10	Glaxo Group Limited	Dérivés de tétrahydrocarbazolones
GB8518742D0 (en) *	1985-07-24	1985-08-29	Glaxo Group Ltd	Process
GB8518741D0 (en) *	1985-07-24	1985-08-29	Glaxo Group Ltd	Process
CA2106642C (fr) *	1992-10-14	2005-08-16	Peter Bod	Derives de carbazolone et procede d'obtention
YU32003A (sh) *	2000-10-30	2006-05-25	Teva Pharmaceutical Industries Ltd.	Novi kristalni i solvatni oblici ondansteron hlorovodonika i postupci za njihovo pripremanje
PL368837A1 (en) *	2001-01-11	2005-04-04	Teva Pharmaceutical Industries Ltd.	An improved process for preparing pure ondansetron hydrochloride dihydrate
CN1665803A (zh) *	2002-04-30	2005-09-07	特瓦药厂有限公司	新晶形的昂丹司琼及其制备方法、含有该新晶形的药物组合物以及用其治疗恶心的方法

2003
- 2003-03-06 FI FI20030093U patent/FI6164U1/fi not_active IP Right Cessation
- 2003-03-11 NL NL1022893A patent/NL1022893C2/nl not_active IP Right Cessation
- 2003-03-14 AU AU2003222765A patent/AU2003222765A1/en not_active Abandoned
- 2003-03-14 WO PCT/EP2003/002745 patent/WO2004063189A1/fr not_active Ceased
- 2003-03-14 EP EP03718690A patent/EP1581519A1/fr not_active Withdrawn
- 2003-03-26 GB GB0306944A patent/GB2398566A/en not_active Withdrawn
- 2003-04-08 DK DK200300114U patent/DK200300114U3/da not_active IP Right Cessation
- 2003-04-08 AU AU2003203580A patent/AU2003203580A1/en not_active Abandoned
- 2003-07-02 FR FR0308044A patent/FR2849852A1/fr active Pending
2004
- 2004-01-02 US US10/750,211 patent/US20040198794A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040198794A1 (en)	2004-10-07
NL1022893C2 (nl)	2004-07-13
GB0306944D0 (en)	2003-04-30
GB2398566A (en)	2004-08-25
AU2003203580A1 (en)	2004-07-29
FR2849852A1 (fr)	2004-07-16
FIU20030093U0 (fi)	2003-03-06
AU2003222765A1 (en)	2004-08-10
FI6164U1 (fi)	2004-03-15
EP1581519A1 (fr)	2005-10-05
WO2004063189A1 (fr)	2004-07-29

Publication	Publication Date	Title
BE1015847A3 (nl)	2005-10-04	Vormen van ondansetron en processen voor het maken van deze.
EP2909191B1 (fr)	2019-03-20	Système cristallin multicomposant comprenant du nilotinib et des formateurs de co-cristal sélectionnés
US7459449B2 (en)	2008-12-02	Stable salts of olanzapine
JPH04266824A (ja)	1992-09-22	医薬品
EP0277738B1 (fr)	1992-03-18	Sel de sodium cristallin et anhydre de 5-chloro-3-(2-thenoyle)-2-oxindole-1-carboxamide
US20030191347A1 (en)	2003-10-09	Venlafaxine base
US6717015B2 (en)	2004-04-06	Venlafaxine besylate
CA2433366C (fr)	2006-01-24	Base libre d'amlodipine
JP7168447B2 (ja)	2022-11-09	ビラスチンの結晶形態及びそれらの調製方法
EP1636176A2 (fr)	2006-03-22	Forme polymorphe de l'acide 4- 6-acetyl-3- 3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyrique
RU2193560C2 (ru)	2002-11-27	Новая соль
AU2004238537A1 (en)	2004-11-25	Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
DK200300114U3 (da)	2004-04-23	Faste tilstandsformer af ondansetron
CN102197035A (zh)	2011-09-21	舒尼替尼的结晶形式及其制备方法
US9682988B2 (en)	2017-06-20	Solid salt form of α-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2005000242A2 (fr)	2005-01-06	Procede d'obtention de l'acide 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]butyrique, polymorphe de forme a
US7335380B2 (en)	2008-02-26	Amlodipine free base
WO2000008016A1 (fr)	2000-02-17	Sels de paroxetine
EP1355632A1 (fr)	2003-10-29	Base libre d'amlodipine
KR20110038781A (ko)	2011-04-15	무정형 아데포비아 디피복실을 포함하는 약학 조성물 및 이의 제조 방법
WO2008056202A2 (fr)	2008-05-15	Mélanges de formes cristallines de désloratadine à faible taux de solvants résiduels

Legal Events

Date	Code	Title	Description
2009-11-27	UBP	Utility model lapsed